Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
about
Sacral neuromodulation in overactive bladder: a review and current perspectivesContrasting the percutaneous nerve evaluation versus staged implantation in sacral neuromodulation.Expanding the Role of Neuromodulation for Overactive Bladder: New Indications and Alternatives to DeliveryCost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention.Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study.The Worldwide Economic Impact of Neurogenic Bladder.Effect of weight loss on urinary incontinence in womenThe effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured populationUnderstanding the dissemination of sacral neuromodulation.Neuromodulation for intractable OAB.Botulinum toxin for conditions of the female pelvis.Cost-effectiveness of novel therapies for overactive bladder.A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK.What is the true catheterization rate after intravesical onabotulinumtoxinA injection?Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.Sacral neuromodulation in urological indications: the Finnish experience.
P2860
Q28066372-C2259E7A-F466-4455-98D1-E2956D6D6B10Q34014583-83232E9D-4C5B-4102-B2D1-173AEF7D64C5Q34703364-9435F113-1B4E-4884-BD7B-E2AC5CF2C81EQ35237161-620B97B5-943B-4FE5-AE13-6C76C956DEF0Q35822811-BF37F486-B23C-4D86-936B-BEA401C866CBQ36101488-E97FA483-5595-4FAD-8F3B-79669BDCAF73Q36450134-2763BFA5-25A4-415B-8149-AFF943116018Q37283761-8AAC764C-1E50-4874-8628-410072F81AEBQ37381500-726154CD-A0BA-4555-930A-0790C6654DB0Q37431886-4581CF48-8329-4A5F-BD7F-B1CA55C3A8D0Q37887667-99F30870-612B-4EDB-84BF-9836DEA8CA2AQ38076295-AED79746-B5A2-4DAB-ACFF-734C904CE94AQ38210254-A00AFF22-13B0-4954-96E1-2E55963DB947Q38345883-5D428219-EFAC-4801-B3B5-42B4980752D4Q45908343-4F1DC586-A478-4DF8-B8C2-3708408A7A1BQ47667519-A232DBC9-05A4-4021-BB57-97F4F2315640Q48304126-C6D028AF-5319-4CCA-9059-76E9022042A0Q51047035-3EFB8F98-8D4C-4BB9-915D-FB04469416CDQ51054121-992867D6-7804-4DB8-AE88-EE235DCB024BQ51536659-59D2DA21-C48A-4AAD-962F-335FF140CE7C
P2860
Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@en
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@nl
type
label
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@en
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@nl
prefLabel
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@en
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@nl
P2093
P1476
Cost-effectiveness of sacral n ...... refractory urge incontinence.
@en
P2093
Anthony G Visco
Cindy L Amundsen
Evan R Myers
Jennifer M Wu
Nazema Y Siddiqui
P304
P356
10.1016/J.JURO.2009.08.031
P407
P577
2009-10-17T00:00:00Z